{"success":true,"data":{"pressRelease":{"id":"133215","rtpr_id":"nGNX3b5FN9","ticker":"RLAY","exchange":"NASDAQ","all_tickers":["RLAY"],"title":"Relay Therapeutics to Participate in Two Upcoming Investor Conferences in September","author":"Globe Newswire","published_at":"2026-09-01T20:46:50.093Z","article_body":"CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc.\n(https://www.globenewswire.com/Tracker?data=IeYlA_dsOK_a0kXiNLu9o6JHJTCZeSlUBfVWMTPwU0vfXgxfn-wLTjRyOcpBC-g9oj6n6eMVaUugUOpn7ImB2Cht9bjWj-93bf_OfYizFpY=)\n(Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company\ndeveloping potentially life-changing therapies for patients living with cancer\nand genetic disease, today announced that management will participate in two\nupcoming fireside chats in September:\n* 2026 Wells Fargo Healthcare Conference on Tuesday, September 8, 2026 at 1:30\np.m. ET\n* Morgan Stanley 24th Annual Global Healthcare Conference on Wednesday,\nSeptember 16, 2026 at 9:15 a.m. ET\nThe fireside chats will be webcast live and may be accessed through Relay\nTherapeutics’ website under Events in the News & Events section through the\nfollowing link: https://ir.relaytx.com/news-events/events-presentations. An\narchived replay of the webcast will be available for up to 30 days following\nthe event.\n\nAbout Relay Therapeutics\n\nRelay Therapeutics (Nasdaq: RLAY) is a clinical-stage, small molecule\nprecision medicine company developing potentially life-changing therapies\nfor patients living with cancer and genetic disease. Relay Therapeutics’\nDynamo(®) platform integrates an array of leading-edge computational and\nexperimental approaches designed to drug protein targets that have previously\nbeen intractable or inadequately addressed. The company’s lead clinical\nasset, zovegalisib, is the first pan-mutant selective PI3Kα inhibitor to\nenter clinical development and is currently in a Phase 3 clinical trial\n(ReDiscover-2) in HR+/HER2- metastatic breast cancer. Zovegalisib is also\nbeing investigated in a group of genetic disease indications called\nPI3Kα-driven vascular anomalies. Relay Therapeutics’ pipeline also includes\nprograms for NRAS-driven solid tumors and Fabry disease. For more information,\nplease visit www.relaytx.com or follow us on LinkedIn\n(https://www.globenewswire.com/Tracker?data=U2A1SADMOQU1a0AZYZLGR-J1Ez9jQZ6Tk_6rlKXInvGQfjznW3dgLV3RQGIjqguf7PcmYDNZrcJ8xIcCaXGCVRFc9zsmjv_jzpwlDsIW3laT11nWUgoxH3iHSJyn0LtPPie9x7AgnqFrX0i59x0NGaDKo5sdNzy98-30HWx938nEgr9bSVWryYlSlf2KE3ec6L2AyAdCY3_QF8_22hUs0A==).\n\nContact:\nMitch Maisel\nmmaisel@relaytx.com\n\nMedia:\nKatie Engleman\n1AB\n919-333-7722\nkatie@1abmedia.com  \n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/079b6db5-ce81-4a81-9cde-d97f86c569ae)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX3b5FN9","title":"Relay Therapeutics to Participate in Two Upcoming Investor Conferences in September","author":"Globe Newswire","ticker":"RLAY","created":"2026-09-01T20:46:50.093Z","tickers":["RLAY"],"exchange":"NASDAQ","article_body":"CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc.\n(https://www.globenewswire.com/Tracker?data=IeYlA_dsOK_a0kXiNLu9o6JHJTCZeSlUBfVWMTPwU0vfXgxfn-wLTjRyOcpBC-g9oj6n6eMVaUugUOpn7ImB2Cht9bjWj-93bf_OfYizFpY=)\n(Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company\ndeveloping potentially life-changing therapies for patients living with cancer\nand genetic disease, today announced that management will participate in two\nupcoming fireside chats in September:\n* 2026 Wells Fargo Healthcare Conference on Tuesday, September 8, 2026 at 1:30\np.m. ET\n* Morgan Stanley 24th Annual Global Healthcare Conference on Wednesday,\nSeptember 16, 2026 at 9:15 a.m. ET\nThe fireside chats will be webcast live and may be accessed through Relay\nTherapeutics’ website under Events in the News & Events section through the\nfollowing link: https://ir.relaytx.com/news-events/events-presentations. An\narchived replay of the webcast will be available for up to 30 days following\nthe event.\n\nAbout Relay Therapeutics\n\nRelay Therapeutics (Nasdaq: RLAY) is a clinical-stage, small molecule\nprecision medicine company developing potentially life-changing therapies\nfor patients living with cancer and genetic disease. Relay Therapeutics’\nDynamo(®) platform integrates an array of leading-edge computational and\nexperimental approaches designed to drug protein targets that have previously\nbeen intractable or inadequately addressed. The company’s lead clinical\nasset, zovegalisib, is the first pan-mutant selective PI3Kα inhibitor to\nenter clinical development and is currently in a Phase 3 clinical trial\n(ReDiscover-2) in HR+/HER2- metastatic breast cancer. Zovegalisib is also\nbeing investigated in a group of genetic disease indications called\nPI3Kα-driven vascular anomalies. Relay Therapeutics’ pipeline also includes\nprograms for NRAS-driven solid tumors and Fabry disease. For more information,\nplease visit www.relaytx.com or follow us on LinkedIn\n(https://www.globenewswire.com/Tracker?data=U2A1SADMOQU1a0AZYZLGR-J1Ez9jQZ6Tk_6rlKXInvGQfjznW3dgLV3RQGIjqguf7PcmYDNZrcJ8xIcCaXGCVRFc9zsmjv_jzpwlDsIW3laT11nWUgoxH3iHSJyn0LtPPie9x7AgnqFrX0i59x0NGaDKo5sdNzy98-30HWx938nEgr9bSVWryYlSlf2KE3ec6L2AyAdCY3_QF8_22hUs0A==).\n\nContact:\nMitch Maisel\nmmaisel@relaytx.com\n\nMedia:\nKatie Engleman\n1AB\n919-333-7722\nkatie@1abmedia.com  \n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/079b6db5-ce81-4a81-9cde-d97f86c569ae)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-09-01T20:46:50.129832876Z","server_sent_at_ms":1788295610129},"received_at":"2026-09-01T20:46:50.216Z","source_url":"https://www.globenewswire.com/news-release/2026/09/01/3354648/0/en/relay-therapeutics-to-participate-in-two-upcoming-investor-conferences-in-september.html"},"analysis":{"id":"122104","press_release_id":"133215","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"other","narrative":"Relay Therapeutics announced that management will participate in fireside chats at the 2026 Wells Fargo Healthcare Conference on September 8 and the Morgan Stanley 24th Annual Global Healthcare Conference on September 16.\n\nBoth sessions will be webcast live via the company's investor relations website, with archived replays available for 30 days following the events.\n\nRelay Therapeutics is a clinical-stage precision medicine company focused on cancer and genetic diseases, with its lead asset zovegalisib currently in a Phase 3 trial for HR+/HER2- metastatic breast cancer.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Routine conference attendance without material disclosures."},"keyFigures":null,"quotedText":"","namedEntities":{"people":[],"products":["Dynamo","zovegalisib"],"companies":[{"name":"Relay Therapeutics, Inc.","ticker":"RLAY"},{"name":"Wells Fargo","relationship":"conference organizer"},{"name":"Morgan Stanley","relationship":"conference organizer"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Routine announcement regarding management participation in upcoming investor conferences. No new clinical data, financial results, or material business developments disclosed."},"tickerRelevance":{"others":[],"primary":"RLAY"},"globalImportance":10,"audienceRelevance":15,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-mid_cap","eventGravity":"routine_conference","sectorWeight":"biotech"}},"event_type":"other","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Relay Therapeutics announced that management will participate in fireside chats at the 2026 Wells Fargo Healthcare Conference on September 8 and the Morgan Stanley 24th Annual Global Healthcare Conference on September 16.\n\nBoth sessions will be webcast live via the company's investor relations website, with archived replays available for 30 days following the events.\n\nRelay Therapeutics is a clinical-stage precision medicine company focused on cancer and genetic diseases, with its lead asset zovegalisib currently in a Phase 3 trial for HR+/HER2- metastatic breast cancer.","key_figures":null,"named_entities":{"people":[],"products":["Dynamo","zovegalisib"],"companies":[{"name":"Relay Therapeutics, Inc.","ticker":"RLAY"},{"name":"Wells Fargo","relationship":"conference organizer"},{"name":"Morgan Stanley","relationship":"conference organizer"}],"dollarAmounts":[]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-01T21:21:27.834Z","global_importance":10,"audience_relevance":15,"importance_components":{"tickerTier":"small-mid_cap","eventGravity":"routine_conference","sectorWeight":"biotech"}},"durationMs":69113,"modelName":"glm-4.7"}}